5F-MDMB-PINACA	Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
AB-CHMINACA	N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide
ADB-CHMNACA	N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide
CB1	Cannabinoid receptor type 1
CB2	Cannabinoid receptor type 2
DUID	Driving under the influence of drugs
EMCDDA	European Monitoring Centre for Drugs and Drug Addiction
GC-IMS	Gas chromatography-ion mobility spectrometry
GC-MS/MS	Gas chromatography-tandem mass spectrometry
HLM	Human liver microsomes
HRMS	High-resolution mass spectrometry
IA	Immunoassays
LC-HRMS	Liquid chromatography/high-resolution mass spectrometry
LC-MS/MS	Liquid chromatography-tandem mass spectrometry
LC-QTOF-MS	Liquid chromatography-quadrupole time-of-flight mass spectrometry
LLE	Liquid-liquid extraction
LLOQ	Lower limit of quantification
LOD	Limit of detection
LOI	Limit of identification
MDMB-CHMICA	Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indol-3-yl]formamido}-3,3-dimethylbutanoate
MEPS	Semi-automated microextraction by packed sorbent
MS	Mass spectrometry
MS/MS	Tandem mass spectrometry
MTBE	Methyl tertiary-butyl ether
NPS	New psychoactive substances
OF	Oral fluid
PRISMA	Preferred reporting items for systematic reviews and meta-analysis
QTOF	Quadruple time of flight
SC/SCs	Synthetic cannabinoid/synthetic cannabinoids
SLE	Supported liquid extraction
SLE	Supported liquid extraction
SPDE	Solid-phase dispersive extraction
SPE	Solid-phase extraction
THC	Tetrahydrocannabinol
UHPLC-QTOF-MS	Ultra-high pressure liquid chromatography quadrupole time-of-flight mass spectrometry